Colesevelam added to com- bination therapy with a statin and ezetimibe in patients with familial hypercholesterolemia: a 12-week, multicenter, randomized, double- blind, controlled trial. Clin Ther. 2010;32:615 25. S4.2-12. Ross S, D Mello M, Anand SS, et al. Effect of bile acid sequestrants on the risk of cardiovascular events: a Mendelian randomization analysis. Circ Cardiovasc Genet. 2015;8:618 27. S4.2-13. Kastelein JJ, Ginsberg HN, Langslet G, et al. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur Heart J. 2015;36:2996 3003. S4.2-14. Perez de Isla L, Alonso R, Mata N, et al. Predicting cardiovascular events in familial hypercholesterolemia: the SAFEHEART Registry (Spanish Familial Hypercholesterolemia Cohort Study). Circulation. 2017;135:2133 44. S4.2-15. Raal FJ, Stein EA, Dufour R, et al. PCSK9 inhibition with evo- locumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;385:331 40. S4.2-16. Nicholls SJ, Brandrup-Wognsen G, Palmer M, et al. Meta-analysis of comparative efficacy of increasing dose of atorvastatin versus rosu- vastatin versus simvastatin on lowering levels of atherogenic lipids (from VOYAGER). Am J Cardiol. 2010;105:69 76. S4.2-17. Pedersen SB, Langsted A, Nordestgaard BG. Nonfasting mild-to- moderate hypertriglyceridemia and risk of acute pancreatitis. JAMA Intern Med. 2016;176:1834 42. S4.2-18. Robinson JG, Huijgen R, Ray K, et al. Determining when to add nonstatin therapy: a quantitative approach. J Am Coll Cardiol. 2016;68:2412 21. S4.2-19. Vallejo-Vaz AJ, Robertson M, Catapano AL, et al. Low-density lipo- protein cholesterol lowering for the primary prevention of cardio- vascular disease among men with primary elevations of low-density lipoprotein cholesterol levels of 190 mg/dL or above: analyses from the WOSCOPS (West of Scotland Coronary Prevention Study) 5-year randomized trial and 20-year observational follow-up. Circulation. 2017;136:1878 91. S4.2-20. Bohula EA, Morrow DA, Giugliano RP, et al. 